GABA-A receptor
Assets acting on this target.
- Class
- GABA-A receptor positive allosteric modulator
The GABA-A receptor is a chloride-channel embedded in nerve cell membranes that responds to gamma-aminobutyric acid (GABA), the principal inhibitory chemical messenger in the brain. When GABA binds, the channel opens, chloride ions flow into the neuron, and the cell becomes less likely to fire. Positive allosteric modulators (PAMs) do not open this channel by themselves in the classic case; instead, they bind at sites separate from where GABA binds and increase how effectively GABA opens the channel, amplifying inhibitory signaling. Because GABA-A receptors are built from different combinations of subunit proteins, several distinct allosteric sites exist, and different chemical classes of PAMs (benzodiazepines, barbiturates, and neurosteroids) each target a different one, producing overlapping but not identical effects on the nervous system. This mechanism is central to controlling seizures, since strengthening inhibition can halt the excessive, synchronized neuronal firing that defines epilepsy and status epilepticus. It also underlies treatments for acute anxiety, procedural sedation, and, in the case of neurosteroid-based modulators, conditions tied to hormonal fluctuation. The shared endpoint across these agents is dampening neuronal excitability broadly, making the receptor a foundational target across neurology and psychiatry.
By indication
Related mechanisms
GABA-A receptor drugs compared
15 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Clobazam (Onfi)Onfi | H. Lundbeck, Lundbeck LLC | small molecule | Approved | Approved in Developmental and Epileptic Encephalopathies; Approved in Epilepsy; Approved in Lennox-Gastaut Syndrome |
| Diazepam (Diastat)Diastat | Bausch Health | small molecule | Approved | Approved in Epilepsy |
| Diazepam (Valium)Valium | Chong Kun Dang Pharmaceutical, Pharmanovia, Waylis Therapeutics LLC | small molecule | Approved | Approved in Epilepsy |
| Diazepam (Valtoco)Valtoco | Neurelis, Inc. | small molecule | Approved | Approved in Epilepsy |
| Ganaxolone | Immedica Pharma AB | small molecule | Approved | Approved in Developmental and Epileptic Encephalopathies; Approved in Epilepsy |
| Lorazepam | Hikma Pharmaceuticals PLC | small molecule | Approved | Approved in Epilepsy |
| Midazolam (Nayzilam)Nayzilam | UCB | small molecule | Approved | Approved in Epilepsy |
| Phenobarbital sodium injection (Sezaby) | Sun Pharmaceutical Industries | small molecule | Approved | Approved in Epilepsy |
| Stiripentol | Biocodex | small molecule | Approved | Approved in Developmental and Epileptic Encephalopathies; Approved in Dravet Syndrome; Approved in Epilepsy; Phase 3 in Primary Hyperoxaluria Type 1 |
| Diazepam (Libervant)Libervant | Aquestive Therapeutics, Inc., Eton Pharmaceuticals, Inc., Pharmanovia | small molecule | Phase 3 | Phase 3 in Epilepsy |
| KH607 | Chengdu Kanghong Pharmaceutical | small molecule | Phase 3 | Phase 3 in Major Depressive Disorder |
| Staccato Alprazolam | Nova Pneuma Inc., UCB | small molecule | Phase 3 | Phase 3 in Epilepsy |
| GlyphAllo (allopregnanolone prodrug)SPT-300 | PureTech Health, Seaport Therapeutics | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| HS-10353 | Hansoh Pharmaceutical Group | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| Remimazolam | Jiangsu Hengrui Pharmaceuticals | small molecule | Phase 1 | Not recorded |